Clinical trial
A Phase 1 Study of bb21217, an Anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma
NCT03274219 is registered in ClinicalTrials.gov with 2seventy bio as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study of bb21217, an Anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma
- Lead sponsor
- 2seventy bio
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 16, 2017
- Completion date
- December 2, 2022
- Enrollment
- 72 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.